Related Experiment Videos
Coagulopathy in prostate cancer.
C de la Fouchardière1, A Flechon, J P Droz
1Department of Medical Oncology, Centre Léon-Bérard, 28 rue Laennec, 69008 Lyon, France.
The Netherlands Journal of Medicine
|February 11, 2004
Summary
Metastatic prostate cancer can cause severe bleeding and clotting issues. This study details a case of recurrent disseminated intravascular coagulation (DIC) and reviews other blood clotting disorders linked to advanced prostate cancer.
Area of Science:
- Hematology
- Oncology
Background:
- Prostate carcinoma, particularly in its metastatic hormone-refractory stage, is associated with significant hemostatic complications.
- Coagulopathies represent a serious, potentially life-threatening challenge in managing advanced prostate cancer.
Observation:
- A case of relapsing disseminated intravascular coagulation (DIC) in a patient with metastatic hormone-refractory prostate carcinoma is presented.
- The review encompasses various coagulation disorders that can arise during the progression of prostate cancer.
Findings:
- Disseminated intravascular coagulation (DIC) is the most prevalent coagulation complication observed in prostate cancer.
- Other associated coagulopathies include thrombotic thrombocytopenic purpura, thrombosis, Trousseau's syndrome, and acquired factor VIII inhibitor development.
Implications:
- Understanding these coagulation complications is crucial for effective patient management and treatment strategies.
- Early recognition and management of DIC and other coagulopathies can improve outcomes for patients with advanced prostate cancer.